<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089178</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0937</org_study_id>
    <nct_id>NCT02089178</nct_id>
  </id_info>
  <brief_title>Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of total intravenous anesthesia and
      inhalation anesthesia on cancer cell cytotoxicity, micrometastasis and recurrence of tumor in
      patients undergoing breast tumor resection. Using propofol-remifentanil in total intravenous
      anesthesia group and sevoflurane -remifentanil in inhalation anesthesia group.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of NK cell</measure>
    <time_frame>at 24 hour after surgery.</time_frame>
    <description>comparison of the effect of total intravenous anesthesia and inhalation anesthesia on cancer cell cytotoxicity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the total intravenous anesthesia group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhalation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the inhalation anesthesia group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravenous anesthesia</intervention_name>
    <description>total intravenous anesthesia group: propofol-remifentanil</description>
    <arm_group_label>intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>inhalation anesthesia</intervention_name>
    <description>inhalation anesthesia group: sevoflurane-remifentanil</description>
    <arm_group_label>inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol-remifentanil</intervention_name>
    <arm_group_label>intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane-remifentanil</intervention_name>
    <arm_group_label>inhalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient between 20 and 65 of age with ASA physical status Ⅰ-Ⅲ

          -  breast cancer patients with no sign of local invasion (adjacent organs) and distant
             metastasis revealed by imaging studies

          -  surgery performed by the same surgical team

        Exclusion Criteria:

          -  ASA physical status Ⅳ

          -  hepatic and renal impairment

          -  diabetes or other endocrine disorders

          -  body mass index &gt; 35 kg/m2

          -  immune disorders or immunosuppressive therapy

          -  steroid treatment in the last 6 months

          -  inflammation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bon Nyeo Koo, MD</last_name>
    <phone>82-2-2228-2420</phone>
    <email>koobn@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bon Nyeo Koo, MD</last_name>
      <phone>82-2-2228-2420</phone>
      <email>koobn@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Bon Nyeo Koo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total intravenous anesthesia, inhalation anesthesia, cancer cell cytotoxicity, breast tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

